10,724 Shares in Dynavax Technologies Co. (NASDAQ:DVAX) Purchased by Centiva Capital LP

Centiva Capital LP purchased a new stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) in the third quarter, according to the company in its most recent filing with the SEC. The fund purchased 10,724 shares of the biopharmaceutical company’s stock, valued at approximately $119,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Dynavax Technologies by 1.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 118,037 shares of the biopharmaceutical company’s stock valued at $1,326,000 after buying an additional 1,172 shares during the last quarter. SummerHaven Investment Management LLC raised its holdings in shares of Dynavax Technologies by 2.4% in the second quarter. SummerHaven Investment Management LLC now owns 54,926 shares of the biopharmaceutical company’s stock valued at $617,000 after purchasing an additional 1,303 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Dynavax Technologies by 44.6% during the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 1,679 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Dynavax Technologies by 175.5% during the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 1,685 shares during the last quarter. Finally, Louisiana State Employees Retirement System grew its position in Dynavax Technologies by 3.0% in the 2nd quarter. Louisiana State Employees Retirement System now owns 65,900 shares of the biopharmaceutical company’s stock worth $740,000 after purchasing an additional 1,900 shares in the last quarter. 96.96% of the stock is owned by institutional investors.

Dynavax Technologies Trading Down 0.2 %

Shares of Dynavax Technologies stock opened at $12.96 on Friday. The firm has a market cap of $1.70 billion, a PE ratio of 99.70 and a beta of 1.33. Dynavax Technologies Co. has a 1 year low of $9.74 and a 1 year high of $15.01. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The stock has a fifty day moving average price of $11.98 and a 200-day moving average price of $11.47.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $29.00 target price on shares of Dynavax Technologies in a research report on Friday, November 8th.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.